Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients

NCT01416402 | Completed Phase 2

• 1 other identifier: M102-21124
• Study Type: interventional
• Target: 27
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to determine whether arhalofenate is safe and effective when dosed in combination with febuxostat in lowering serum uric acid in patients with gout.

Conditions

Hyperuricemia; Gout

Keywords

Hyperuricemia; gout; serum uric acid

Outcome Measures

Primary Outcomes (1)

• Proportion of patients achieving sUA <6.0 mg/dL, <5.0 mg/dL, <4.0 mg/dL and <3.0 mg/dL at the end of combination treatment period with each of the doses of arhalofenate

  36 days

Study Arms (1)

Arhalofenate with febuxostat and colchicine

OTHER

Drug: Arhalofenate; Drug: Febuxostat; Drug: Colchicine

Interventions

Arhalofenate DRUG

400 mg once daily orally for two weeks then up-titrated to 600 mg once daily orally for an additional two weeks

Also known as: MBX-102

Arhalofenate with febuxostat and colchicine

Febuxostat DRUG

80 mg once daily orally for 5 weeks

Also known as: Uloric

Arhalofenate with febuxostat and colchicine

Colchicine DRUG

Colchicine 0.6 mg daily as prophylaxis to prevent gout flares

Also known as: Colcrys

Arhalofenate with febuxostat and colchicine

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Known gout patient (per criteria of the American Rheumatism Association for the classification of the acute arthritis of primary gout in Appendix 3) with a serum uric acid value of at least 8.0 mg/dL at Screening Visit. Patients on allopurinol must agree to discontinue their existing therapy at Visit 1 through the entire duration of the study and must have a sUA value of at least 8.0 mg/dL after a minimum 2 week wash-out at Visit 2.
• Male or female, 18-75 years of age at Screening Visit
• All female patients must be surgically sterile or post-menopausal (at least 45 years of age with no history of menses for at least 2 years; or any age with no history of menses for at least 6 months and serum FSH ≥ 40 mIU/mL) or must agree to use two medically accepted methods of contraception including a barrier method (see the list in Appendix 4) for the entire duration of the study unless report of complete sexual abstinence.
• Female patients must not be pregnant or lactating
• Male patients with a female partner of child-bearing potential must agree to use condom or the partner must use a medically acceptable method of contraception for the entire duration of the study.
• Estimated CrCl ≥ 50 mL/min as calculated by the by Cockcroft-Gault method
• Serum creatinine value must be ≤ 1.3 mg/dL in females and ≤ 1.4 mg/dL in males
• Patients must have liver function tests (LFTs) ≤ 1.5X ULN for AST, ALT and T-bilirubin, ≤ 2X ULN for ALP, ≤ 3X ULN for GGT; CK ≤ 3X ULN
• All other clinical laboratory parameters must be within normal limits or considered not clinically significant
• Electrocardiogram (ECG) must be normal, or if abnormal, considered not clinically significant
• Patients must have a systolic blood pressure ≤ 160 mm Hg and a diastolic blood pressure ≤ 95 mm Hg; known hypertensive patients controlled with medication other than diuretics (BP reading as above) may be included
• Patients must agree to remain in-clinic for 37 days consecutively and agree to follow the study procedures as described in the protocol

You may not qualify if:

• Treatment with any ULT other than allopurinol (e.g., probenecid, benzbromarone, febuxostat, or pegloticase) within two weeks of the Screening Visit
• Known or suspected secondary hyperuricemia (e.g. due to myeloproliferative disorder, or organ transplant).
• Diagnosis of xanthinuria
• History of documented or suspected kidney stones
• Known infection with the human immunodeficiency virus (HIV) or history of viral hepatitis type B or C
• History of illicit drug or alcohol abuse within one year of Screening Visit
• History of significant pulmonary disease, upper gastrointestinal (GI) bleeding, documented peptic ulcer disease (unless known H. pylori infection treated successfully without recurrence), or nephrotic syndrome within three years of Screening Visit
• History of stroke, TIA, acute myocardial infarction (MI), congestive heart failure (CHF) (NYHA Class II-IV), angina pectoris, coronary intervention procedure (including but not limited to angioplasty, stent placement, coronary revascularization), lower extremity bypass procedure, systemic or intracoronary fibrinolytic therapy within 5 years of screening
• Malignancy within five years of Screening Visit (except successfully treated basal cell carcinoma)
• Body mass index (BMI) \> 42 kg/m2
• Current or expected requirement for anticoagulant therapy \[except for low-dose (≤ 325 mg/day) aspirin and/or Plavix® 75 mg/day\]
• Rheumatoid arthritis or other autoimmune disease requiring ongoing treatment
• Current or expected treatment with potent CYP3A4 inhibitors (See Appendix 6), cytotoxic agents (azathioprine, mercaptopurine, cyclosporine, cyclophosphamide, etc.), ranolazine, digoxin, theophyline, desipramine, sulphonylurea, thiazolidinedione, diuretics, atypical antipsychotic agents, or phenytoin
• Chronic treatment with non-steroidal anti-inflammatory drugs (NSAIDs use to treat acute gout flares is permitted)
• Current or expected treatment with systemic corticosteroids (except topical, ophthalmic, intra-articular, or inhaled at a dose \< 1600 μg/day) other than to treat acute gout flares

Sponsors & Collaborators

• Gilead Sciences: lead

Study Sites (1)

Unknown Facility

Overland Park, Kansas, 66212, United States

Location

MeSH Terms

Conditions

Hyperuricemia; Gout

Interventions

arhalofenate; Febuxostat; Colchicine

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms; Arthritis; Joint Diseases; Musculoskeletal Diseases; Crystal Arthropathies; Rheumatic Diseases; Purine-Pyrimidine Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Metabolic Diseases; Nutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Thiazoles; Sulfur Compounds; Organic Chemicals; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Alkaloids

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 11, 2011
• First Posted: August 15, 2011
• Study Start: August 1, 2011
• Primary Completion: October 1, 2011
• Study Completion: October 1, 2011
• Last Updated: April 3, 2015

Record last verified: 2015-03

Locations

US (1)